

**Table S1. Observation of Syrian hamsters administered TMR-001 once/day for 10 days**

<b>Group</b>	<b>Appearance</b>	<b>Paresis</b>	<b>Paralysis</b>	<b>Seizure</b>	<b>Self-mutilation</b>	<b>Notes</b>
0.1 mg/kg IP	100% (6/6) redness on lateral ventral side by day 7	0% (0/6)	0% (0/6)	0% (0/6)	0% (0/6)	Mild skin reaction
0.1 mg/kg IM	Normal	0% (0/6)	0% (0/6)	0% (0/6)	0% (0/6)	
0.1 mg/kg IV	Normal	0% (0/5)	0% (0/5)	0% (0/5)	0% (0/5)	1 euthanized due to problem with catheter day 0

**Figure S1. Effect of TMR-001 administration on body weight in healthy animals**

TMR-001 was administered intraperitoneal (IP, green), intramuscular (IM, red), or intravenous (IV, blue) at 0.1 mg/kg once-per-day for 10 days, and animals were observed for 28 days. Group size was 6 hamsters; except IV administration group size was 5 hamsters. The mean body weight in grams (g) and standard deviation for each group over time is shown. By day 4 and continuing to day 28, the average body weight for the IV administration group was significantly lower than both IM and IP groups (two-way ANOVA Tukey’s adjusted  $p$ -values  $<0.05$ ). No other differences were significant. No clinical signs were observed in any of the groups.

Fig. S1

